Dr Sidransky, MD, will continue to serve as Principal Investigator of this Program. The Program has been a major focus of the SPORE because it provides for a continuous flow of innovative ideas and activity to stimulate investigation in the context of SPORE translational research. The Developmental Research Program provides a means to respond to new opportunities, and is designed to encourage and facilitate new research efforts. The Program takes advantage of the broad expertise of researchers at The Johns Hopkins University and of external investigators by providing funds for pilot projects with potential for development into full-fledged translational research avenues, collaborations, and new methodologies for integration into other Research Projects. In most prior years, the Cancer Center has augmented the funding provided to each of our pilot project recipients or extended their duration beyond SPORE support. In the past two years, the formation of an Upper Aerodigestive Tract (DAD) Cancer program within the Oncology Center has also provided support for additional basic and clinical pilot projects that are not intended to be as translational as the goals of the SPORE Developmental Projects. Within this year, we also have gained a commitment for an additional two HN cancer pilot projects to be funded by institutional sources each year. These resources, and funding pressures from a reduced overall budget for the proposed SPORE funding period, have allowed us to shift some of the financial sources from the SPORE to the institution. The mechanism for identification and funding of innovative research has been the same since inception The solicitation is done by announcements of the availability of funding placed in the official Johns Hopkins University and Johns Hopkins Hospital newsletters. Memoranda are sent to all department chairpersons and relevant division heads to announce the yearly solicitation. The required proposal format is brief in order to encourage responses by investigators. We use the PHS 298 format but with one-page limits on each section of the Research Plan. We also solicit applications made through inquiry directly to our SPORE Director or to the leader of the Developmental Research program. The program uses a revolving scoring system whereby two non-SPORE translational faculty of the Cancer Center are appointed by the SPORE PI (DR Sidransky) in addition to all Project Pis. The designation of revolving reviewers to conduct independent evaluations provides an evolving, tradition-free perspective with each round. The revolving reviewers and Dr. Sidransky rate the applications along seven categories: A. Novelty B. Focus of experimental plan C. Preliminary data OR logical rationale alone D. Likely efficiency to achieve the anticipated advance E. Potential translational impact of the advance F. Prospects for fostering faculty interactions G. Prospects for long-term research

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Specialized Center (P50)
Project #
5P50DE019032-09
Application #
8111074
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
9
Fiscal Year
2010
Total Cost
$190,599
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kagohara, Luciane T; Stein-O'Brien, Genevieve L; Kelley, Dylan et al. (2018) Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. Brief Funct Genomics 17:49-63
Windon, Melina J; D'Souza, Gypsyamber; Rettig, Eleni M et al. (2018) Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults. Cancer 124:2993-2999
Ravi, Rajani; Noonan, Kimberly A; Pham, Vui et al. (2018) Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF? enhance the efficacy of cancer immunotherapy. Nat Commun 9:741
Bishop, Justin A; Westra, William H (2018) MYB Translocation Status in Salivary Gland Epithelial-Myoepithelial Carcinoma: Evaluation of Classic, Variant, and Hybrid Forms. Am J Surg Pathol 42:319-325
Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97
Bishop, Justin A; Rooper, Lisa M; Chiosea, Simion I et al. (2018) Clear Cell Carcinoma of Salivary Glands Is Frequently p16 Positive: A Pitfall in the Interpretation of Oropharyngeal Biopsies. Am J Surg Pathol 42:367-371
Afsari, Bahman; Guo, Theresa; Considine, Michael et al. (2018) Splice Expression Variation Analysis (SEVA) for inter-tumor heterogeneity of gene isoform usage in cancer. Bioinformatics 34:1859-1867
Bishop, Justin A; Cowan, Morgan L; Shum, Chung H et al. (2018) MAML2 Rearrangements in Variant Forms of Mucoepidermoid Carcinoma: Ancillary Diagnostic Testing for the Ciliated and Warthin-like Variants. Am J Surg Pathol 42:130-136
Kelley, Dylan Z; Flam, Emily L; Guo, Theresa et al. (2018) Functional characterization of alternatively spliced GSN in head and neck squamous cell carcinoma. Transl Res 202:109-119
Ghantous, Yasmine; Schussel, Juliana L; Brait, Mariana (2018) Tobacco and alcohol-induced epigenetic changes in oral carcinoma. Curr Opin Oncol 30:152-158

Showing the most recent 10 out of 137 publications